Former Medtronic CEO exits retirement early to helm Immucor

William A. Hawkins, former chairman and CEO of Medtronic, will replace outgoing Immucor CEO Joshua Levine, after he steps down from the role Oct. 17, according to a statement from the company’s board of directors.

Hawkins’ career includes more than 30 years in medical technology companies, as well as roles in Washington, D.C., that helped shape healthcare policies and matters involving the FDA. Upon becoming CEO, Hawkins will also serve as senior advisor to TPG Capital, Immucor’s parent company.

Outgoing CEO Levine cited distance from his family as the reason for stepping down from the role.

The Norcross, Ga.-based company develops and sells reagents and systems used to detect and identify cell and serum components of human blood prior to blood transfusions.

Around the web

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.

“Without a more concrete and stable policy on these tariffs from the current American administration, it is likely that most manufacturers will be forced to continuously change their internal forecasts and production plans," one analyst said.